Aspirin is efficacious for the treatment of acute migraine

Richard B. Lipton, Jerome Goldstein, Jeffrey S. Baggish, Alberto R. Yataco, James V. Sorrentino, John N. Quiring

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Background. - More than 50% of migraine sufferers rely on over-the-counter medications for the treatment of migraine. Along with other over-the-counter products, aspirin is considered by the US Headache Consortium to be an option for first-line migraine treatment. This study assessed the efficacy and tolerability of aspirin versus placebo for the acute treatment of a single acute attack of migraine. Methods. - This prospective, randomized, double-blind, parallel-group, placebo-controlled study evaluated the efficacy of a single, 1000-mg dose of aspirin for the treatment of acute moderate to severe migraine, with or without aura. Subjects recorded all study evaluations in a diary at baseline and at .5, 1, 2, 3, 4, 5, 6, and 24 hours after treatment. Pain was rated on a 4-point ordinal scale from no pain to severe pain. The primary efficacy end point was headache response at 2 hours. Secondary efficacy parameters included reduction of nausea, photophobia and phonophobia, pain intensity difference, and headache recurrence at 24 hours. Results. - Of 485 subjects enrolled, 409 took study medication and 401 treated a confirmed migraine attack (201 with aspirin and 200 with placebo). Baseline demographic and migraine characteristics were not significantly different between groups. The 2-hour headache response rate was 52% with aspirin versus 34% with placebo (P < .001). Aspirin was significantly more effective than placebo for pain reduction beginning 1 hour after dosing (P < .001) and continuing throughout the 6-hour evaluation period. Significantly (P < .05), more subjects were pain free from the 1-hour evaluation through the 6-hour evaluation. Of the aspirin-treated subjects, 20% were pain free at 2 hours versus only 6% of placebo-treated subjects. At 24 hours, the headache recurrence rate was 21.8% for aspirin (23 of 105 subjects) and 27.7% for placebo (19 of 68 subjects). Only 34% of aspirin-treated subjects needed rescue medication at 24 hours compared with 52% of placebo-treated subjects (P < .001). Aspirin was well tolerated, and adverse events were not significantly different between groups. Conclusions. - This study demonstrates that aspirin is safe and effective for treatment of acute migraine in appropriately selected patients.

Original languageEnglish (US)
Pages (from-to)283-292
Number of pages10
JournalHeadache
Volume45
Issue number4
DOIs
StatePublished - Apr 2005

Fingerprint

Migraine Disorders
Aspirin
Placebos
Headache
Pain
Therapeutics
Hyperacusis
Migraine without Aura
Migraine with Aura
Recurrence
Photophobia
Nausea
Demography

Keywords

  • Aspirin
  • Efficacy
  • Migraine
  • Safety
  • Treatment

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Lipton, R. B., Goldstein, J., Baggish, J. S., Yataco, A. R., Sorrentino, J. V., & Quiring, J. N. (2005). Aspirin is efficacious for the treatment of acute migraine. Headache, 45(4), 283-292. https://doi.org/10.1111/j.1526-4610.2005.05065.x

Aspirin is efficacious for the treatment of acute migraine. / Lipton, Richard B.; Goldstein, Jerome; Baggish, Jeffrey S.; Yataco, Alberto R.; Sorrentino, James V.; Quiring, John N.

In: Headache, Vol. 45, No. 4, 04.2005, p. 283-292.

Research output: Contribution to journalArticle

Lipton, RB, Goldstein, J, Baggish, JS, Yataco, AR, Sorrentino, JV & Quiring, JN 2005, 'Aspirin is efficacious for the treatment of acute migraine', Headache, vol. 45, no. 4, pp. 283-292. https://doi.org/10.1111/j.1526-4610.2005.05065.x
Lipton RB, Goldstein J, Baggish JS, Yataco AR, Sorrentino JV, Quiring JN. Aspirin is efficacious for the treatment of acute migraine. Headache. 2005 Apr;45(4):283-292. https://doi.org/10.1111/j.1526-4610.2005.05065.x
Lipton, Richard B. ; Goldstein, Jerome ; Baggish, Jeffrey S. ; Yataco, Alberto R. ; Sorrentino, James V. ; Quiring, John N. / Aspirin is efficacious for the treatment of acute migraine. In: Headache. 2005 ; Vol. 45, No. 4. pp. 283-292.
@article{d294f3e4f40545f19b193ec8ae2da62a,
title = "Aspirin is efficacious for the treatment of acute migraine",
abstract = "Background. - More than 50{\%} of migraine sufferers rely on over-the-counter medications for the treatment of migraine. Along with other over-the-counter products, aspirin is considered by the US Headache Consortium to be an option for first-line migraine treatment. This study assessed the efficacy and tolerability of aspirin versus placebo for the acute treatment of a single acute attack of migraine. Methods. - This prospective, randomized, double-blind, parallel-group, placebo-controlled study evaluated the efficacy of a single, 1000-mg dose of aspirin for the treatment of acute moderate to severe migraine, with or without aura. Subjects recorded all study evaluations in a diary at baseline and at .5, 1, 2, 3, 4, 5, 6, and 24 hours after treatment. Pain was rated on a 4-point ordinal scale from no pain to severe pain. The primary efficacy end point was headache response at 2 hours. Secondary efficacy parameters included reduction of nausea, photophobia and phonophobia, pain intensity difference, and headache recurrence at 24 hours. Results. - Of 485 subjects enrolled, 409 took study medication and 401 treated a confirmed migraine attack (201 with aspirin and 200 with placebo). Baseline demographic and migraine characteristics were not significantly different between groups. The 2-hour headache response rate was 52{\%} with aspirin versus 34{\%} with placebo (P < .001). Aspirin was significantly more effective than placebo for pain reduction beginning 1 hour after dosing (P < .001) and continuing throughout the 6-hour evaluation period. Significantly (P < .05), more subjects were pain free from the 1-hour evaluation through the 6-hour evaluation. Of the aspirin-treated subjects, 20{\%} were pain free at 2 hours versus only 6{\%} of placebo-treated subjects. At 24 hours, the headache recurrence rate was 21.8{\%} for aspirin (23 of 105 subjects) and 27.7{\%} for placebo (19 of 68 subjects). Only 34{\%} of aspirin-treated subjects needed rescue medication at 24 hours compared with 52{\%} of placebo-treated subjects (P < .001). Aspirin was well tolerated, and adverse events were not significantly different between groups. Conclusions. - This study demonstrates that aspirin is safe and effective for treatment of acute migraine in appropriately selected patients.",
keywords = "Aspirin, Efficacy, Migraine, Safety, Treatment",
author = "Lipton, {Richard B.} and Jerome Goldstein and Baggish, {Jeffrey S.} and Yataco, {Alberto R.} and Sorrentino, {James V.} and Quiring, {John N.}",
year = "2005",
month = "4",
doi = "10.1111/j.1526-4610.2005.05065.x",
language = "English (US)",
volume = "45",
pages = "283--292",
journal = "Headache",
issn = "0017-8748",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Aspirin is efficacious for the treatment of acute migraine

AU - Lipton, Richard B.

AU - Goldstein, Jerome

AU - Baggish, Jeffrey S.

AU - Yataco, Alberto R.

AU - Sorrentino, James V.

AU - Quiring, John N.

PY - 2005/4

Y1 - 2005/4

N2 - Background. - More than 50% of migraine sufferers rely on over-the-counter medications for the treatment of migraine. Along with other over-the-counter products, aspirin is considered by the US Headache Consortium to be an option for first-line migraine treatment. This study assessed the efficacy and tolerability of aspirin versus placebo for the acute treatment of a single acute attack of migraine. Methods. - This prospective, randomized, double-blind, parallel-group, placebo-controlled study evaluated the efficacy of a single, 1000-mg dose of aspirin for the treatment of acute moderate to severe migraine, with or without aura. Subjects recorded all study evaluations in a diary at baseline and at .5, 1, 2, 3, 4, 5, 6, and 24 hours after treatment. Pain was rated on a 4-point ordinal scale from no pain to severe pain. The primary efficacy end point was headache response at 2 hours. Secondary efficacy parameters included reduction of nausea, photophobia and phonophobia, pain intensity difference, and headache recurrence at 24 hours. Results. - Of 485 subjects enrolled, 409 took study medication and 401 treated a confirmed migraine attack (201 with aspirin and 200 with placebo). Baseline demographic and migraine characteristics were not significantly different between groups. The 2-hour headache response rate was 52% with aspirin versus 34% with placebo (P < .001). Aspirin was significantly more effective than placebo for pain reduction beginning 1 hour after dosing (P < .001) and continuing throughout the 6-hour evaluation period. Significantly (P < .05), more subjects were pain free from the 1-hour evaluation through the 6-hour evaluation. Of the aspirin-treated subjects, 20% were pain free at 2 hours versus only 6% of placebo-treated subjects. At 24 hours, the headache recurrence rate was 21.8% for aspirin (23 of 105 subjects) and 27.7% for placebo (19 of 68 subjects). Only 34% of aspirin-treated subjects needed rescue medication at 24 hours compared with 52% of placebo-treated subjects (P < .001). Aspirin was well tolerated, and adverse events were not significantly different between groups. Conclusions. - This study demonstrates that aspirin is safe and effective for treatment of acute migraine in appropriately selected patients.

AB - Background. - More than 50% of migraine sufferers rely on over-the-counter medications for the treatment of migraine. Along with other over-the-counter products, aspirin is considered by the US Headache Consortium to be an option for first-line migraine treatment. This study assessed the efficacy and tolerability of aspirin versus placebo for the acute treatment of a single acute attack of migraine. Methods. - This prospective, randomized, double-blind, parallel-group, placebo-controlled study evaluated the efficacy of a single, 1000-mg dose of aspirin for the treatment of acute moderate to severe migraine, with or without aura. Subjects recorded all study evaluations in a diary at baseline and at .5, 1, 2, 3, 4, 5, 6, and 24 hours after treatment. Pain was rated on a 4-point ordinal scale from no pain to severe pain. The primary efficacy end point was headache response at 2 hours. Secondary efficacy parameters included reduction of nausea, photophobia and phonophobia, pain intensity difference, and headache recurrence at 24 hours. Results. - Of 485 subjects enrolled, 409 took study medication and 401 treated a confirmed migraine attack (201 with aspirin and 200 with placebo). Baseline demographic and migraine characteristics were not significantly different between groups. The 2-hour headache response rate was 52% with aspirin versus 34% with placebo (P < .001). Aspirin was significantly more effective than placebo for pain reduction beginning 1 hour after dosing (P < .001) and continuing throughout the 6-hour evaluation period. Significantly (P < .05), more subjects were pain free from the 1-hour evaluation through the 6-hour evaluation. Of the aspirin-treated subjects, 20% were pain free at 2 hours versus only 6% of placebo-treated subjects. At 24 hours, the headache recurrence rate was 21.8% for aspirin (23 of 105 subjects) and 27.7% for placebo (19 of 68 subjects). Only 34% of aspirin-treated subjects needed rescue medication at 24 hours compared with 52% of placebo-treated subjects (P < .001). Aspirin was well tolerated, and adverse events were not significantly different between groups. Conclusions. - This study demonstrates that aspirin is safe and effective for treatment of acute migraine in appropriately selected patients.

KW - Aspirin

KW - Efficacy

KW - Migraine

KW - Safety

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=17244372753&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17244372753&partnerID=8YFLogxK

U2 - 10.1111/j.1526-4610.2005.05065.x

DO - 10.1111/j.1526-4610.2005.05065.x

M3 - Article

C2 - 15836564

AN - SCOPUS:17244372753

VL - 45

SP - 283

EP - 292

JO - Headache

JF - Headache

SN - 0017-8748

IS - 4

ER -